| Similarity | Rank | |
|---|---|---|
| Nasdaq | 0.717 | 27770 |
| 52-week | 0.692 | 74848 |
| NASDAQ | 0.657 | 21372 |
| OTC | 0.652 | 21898 |
| FDA | 0.649 | 5193 |
| FDA's | 0.648 | 32675 |
| biologics | 0.637 | 70740 |
| investigational | 0.635 | 62099 |
| NYSE | 0.630 | 17080 |
| analysts' | 0.627 | 68593 |
| better-than-expected | 0.624 | 97932 |
| approvals | 0.621 | 19635 |
| repurchase | 0.620 | 42807 |
| bevacizumab | 0.615 | 94024 |
| AAPL | 0.614 | 48960 |
| second-quarter | 0.613 | 69391 |
| full-year | 0.612 | 55948 |
| IPO | 0.610 | 19002 |
| intraday | 0.607 | 49554 |
| buyback | 0.607 | 55850 |
| Euronext | 0.605 | 84541 |
| CFTC | 0.604 | 49812 |
| buybacks | 0.603 | 88571 |
| Genentech | 0.600 | 73045 |
| exchange-traded | 0.599 | 76223 |